Over a recent six-year period, all but one of the best-selling prescription drugs in the U.S. experienced “substantial” increases in cost, regardless of how long the medicines had been on the market or whether generic competition existed, according to a new study.

Of 49 medicines that were available between 2012 and 2017, the median increase in insurer and out-of-pocket patient costs was 76%. Drilling down further, the researchers looked at the 36 drugs that became available only as of 2012, and they found that costs rose for 28 of them by more than 50%. Prices more than doubled for another 16 medicines. And costs rose at least once, and sometimes twice, each year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy